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Background Vitiligo is the most frequent depigmentation disorder of the skin and is
cosmetically and psychologically devastating. A recently updated Cochrane
systematic review ‘Interventions for vitiligo’ showed that the research evidence
for treatment of vitiligo is poor, making it difﬁcult to make ﬁrm recommenda-
tions for clinical practice.
Objectives To stimulate and steer future research in the ﬁeld of vitiligo treatment,
by identifying the 10 most important research areas for patients and clinicians.
Methods A vitiligo priority setting partnership was established including patients,
healthcare professionals and researchers with an interest in vitiligo. Vitiligo treat-
ment uncertainties were gathered from patients and clinicians, and then priori-
tized in a transparent process, using a methodology advocated by the James Lind
Alliance.
Results In total, 660 treatment uncertainties were submitted by 461 participants.
These were reduced to a list of the 23 most popular topics through an online⁄
paper voting process. The 23 were then prioritized at a face-to-face workshop in
London. The ﬁnal list of the top 10 treatment uncertainties included interventions
such as systemic immunosuppressants, topical treatments, light therapy, melano-
cyte-stimulating hormone analogues, gene therapy, and the impact of psycholog-
ical interventions on the quality of life of patients with vitiligo.
Conclusions The top 10 research areas for the treatment of vitiligo provide guidance
for researchers and funding bodies, to ensure that future research answers ques-
tions that are important both to clinicians and to patients.
Vitiligo is the most common chronic depigmentation disorder
affecting around 0Æ5%
1,2 of the world population. It is cos-
metically and psychologically devastating,
3 and can result in
low self-esteem, poor body image and difﬁculties in sexual re-
lationships.
4–7 The causes of vitiligo are poorly understood
and treatment is often unsatisfactory.
8
Sixty-eight treatments for vitiligo have been evaluated in
clinical trials over the last 43 years. However, due to the small
numbers of participants and heterogeneity of design of trials
to date, it is difﬁcult to make ﬁrm recommendations for clini-
cal practice.
9 Indeed, in the face of so many treatment options
and with so little information regarding their relative efﬁcacy,
it is difﬁcult to identify which clinical trials are most impor-
tant and timely.
In order to address this concern, this project was established
with the aim of helping to identify the following. (i) Which
interventions should be evaluated? (ii) What are the most
important topics to patients and clinicians? (iii) Could these
topics be answered by clinical research?
It is increasingly recognized that patients and healthcare
professionals have a key role to play in identifying important
areas for research. The James Lind Alliance (JLA) is a Depart-
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tiative, which has been established to bring patients and
clinicians together in ‘priority setting partnerships’ (PSPs) to
identify and prioritize the unanswered questions that they
agree are most important.
10 The pharmaceutical and medical
technology industries and academia play an essential role in
developing new treatments.
11 However, the priorities of
industry and academics are not necessarily the same as those
of patients and clinicians. For this reason many areas of poten-
tially valuable research are neglected. Therefore it is essential
that researchers and funding bodies are aware of the needs of
patients and clinicians.
This was the ﬁrst PSP in the ﬁeld of dermatology and the
third of its kind to have been convened by the JLA. Previous




All the uncertainties identiﬁed by the PSPs are added to the
Database of Uncertainties about the Effects of Treatments
(DUETs) in order to provide reference for funding bodies and
researchers. It is known that the research funding bodies in
the U.K. systematically scan important research resources to
identify evidence gaps and make recommendations for
research. This includes Cochrane systematic reviews and more
recently DUETs.
DUETs has been established in the U.K. to publish uncertain-
ties about the effects of treatment which cannot currently be
answered by referring to reliable up-to-date systematic reviews
of existing research evidence.
13 A treatment uncertainty exists
when ‘no up-to-date systematic review exists, or up-to-date
systematic reviews show that uncertainty continues’,
14 i.e.
more research needs to be done to establish the effectiveness
and safety of an existing or innovative intervention.
Materials and methods
The vitiligo PSP was coordinated at the Centre of Evidence
Based Dermatology, University of Nottingham, with numerous
stakeholders from professional organizations and patient sup-
port groups. The aim of the vitiligo PSP was to reduce the
number of uncertainties surrounding the treatment of this
condition and to steer future research to questions of impor-
tance both to people living with the disease and to people
treating the disease.
The vitiligo PSP adopted the methods advocated by the
JLA
11 which were reﬁned to meet the needs of this particular
PSP.
11 The vitiligo PSP had ﬁve stages (see Fig. 1 for a sum-
mary of the vitiligo PSP methodology).
Stage 1: Initiation
The aim of this stage was to establish the vitiligo PSP by
raising awareness, and identifying and engaging potential
stakeholders.
Organizations approached during this stage were profes-
sional bodies and patient support groups: British Association
of Dermatologists (BAD), UK Dermatology Clinical Trials
Network (UK DCTN), NHS Evidence – Skin Disorders, Coch-
rane Skin Group, British Dermatological Nursing Group,
Changing Faces, British Red Cross Camouﬂage Service, Skin
Care Campaign, Primary Care Dermatology Society, Vitiligo
European Task Force, British Association of Skin Camouﬂage
and Vitiligo Society. Individual researchers, dermatologists,
specialist nurses and psychologists with a special interest in
vitiligo were also informed. Our research group, called the
Steering Group, included 12 members with knowledge and
interest in vitiligo. (For details on the Steering Group mem-
bers please see Acknowledgments section).
Stage 1: Initiation
Identification of potential vitiligo priority setting stakeholders: 
British Association of Dermatologists, Vitiligo Society, 
Changing Faces, UK Dermatology Clinical Trials Network, 
Centre of Evidence Based Dermatology, British Association of 
Skin Camouflage, British Red Cross Camouflage Services, Skin 
Care campaign, NHS Evidence- Skin Disorders Library, British 
Dermatological Nursing Group, and the James Lind Alliance. 
Duration: January 2009-March 2009 
Stage 2: Consultation
Identification of uncertainties from: 
(i) updated Cochrane systematic review 
(ii) BAD guidelines  
(iii) consultation survey of patients, carers and clinicians 
Duration: March 2009-August 2009 
Stage 3: Collation
Uncertainties collated. 
Duplicates removed or reworded where appropriate in order 
to create a “long list” of uncertainties. 
All uncertainties entered into the DUETs database. 
Duration: August 2009-December 2009 
Stage 4: Ranking exercise
Identification of the most popular topics (max 25) by voting for 
3 favourite topics. 
Duration: January 2010-February 2010
Stage 5: Final Prioritisation Workshop
Identification of the Top 10 research priorities for the 
treatment of vitiligo through consensus between patients, 
carers and healthcare professionals. 
Duration: 1 day 
Fig 1. Summary of methods used by the vitiligo priority setting
partnership. BAD, British Association of Dermatologists; DUETs,
Database of Uncertainties about the Effects of Treatments.
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The aim of this stage was to collect treatment uncertainties.
An online and paper survey was undertaken that encouraged
patients and clinicians to submit their questions about the
treatment of vitiligo. Paper copies of the questionnaire were
sent to the Vitiligo Society (n = 1268) and to the BAD
(n = 835). E-mails were sent to members of the UK DCTN
(n = 500), and details of the project (with links to the online
survey) were advertised on the websites and in the newsletters
of the relevant organizations listed above.
Additional treatment uncertainties were identiﬁed from
existing sources of current evidence: the updated Cochrane
systematic review ‘Interventions for vitiligo’
9 and the BAD
guideline for diagnosis and management of vitiligo.
15
Stage 3: Collation
The aim of this stage was to create a ‘long-list’ of uncer-
tainties by collating, reﬁning submitted uncertainties and
rewording similar questions. Questions on the aetiology, the
natural history and prevention of the disease (non-treatment
uncertainties) were excluded at this stage. Each collated
uncertainty represented a broad area for research, rather
than focusing on a speciﬁc research question. For example,
the reﬁned uncertainty ‘How effective is ultraviolet B ther-
apy when combined with creams or ointments in treating
vitiligo?’ includes combination of narrowband ultraviolet B
with topical agents such as corticosteroids, calcineurin
inhibitors, vitamin D analogues etc. This was necessary in
order to reduce the list of uncertainties to a manageable
number.
Stage 4: Ranking exercise (Interim prioritization
exercise)
The aim of the ranking exercise was to create a ‘short-list’ of
uncertainties and to reduce their number to no more than 25.
As the majority of participants from the consultation stage
expressed a willingness to engage in the process further, the
ranking exercise included all people who gave contact details
during the consultation. It was also advertised on the websites
and in the newsletters of relevant organizations, as per the
consultation stage. In addition, advertisements and articles
were placed in the Voice magazine for black and ethnic
minorities, the British Dermatological Nursing Group
magazine
16 and the bulletin of the Primary Care Dermatology
Society
17 to target speciﬁc groups that had been under-repre-
sented during the consultation stage.
Participants were asked to vote for their three favourite
topics (three individual votes) online (http://www.
vitiligostudy.org.uk) or using paper questionnaires by down-
loading them from our website or contacting the research
team directly. The order in which uncertainties appeared on
the survey was randomized in order to guard against response
bias.
Stage 5: Final Prioritization Workshop
The aim of this ﬁnal stage was to identify the top 10 most
important treatment uncertainties for vitiligo by creating con-
sensus through a face-to-face workshop of healthcare profes-
sionals and patients.
Participants of previous stages of the vitiligo PSP attended
this workshop. Efforts were made to ensure that equal num-
bers of patients and healthcare professionals attended. The
workshop was a full-day event, held at the London ofﬁces of
the BAD on 25 March 2010.
Further details of the methods used during the vitiligo PSP
are outlined in the James Lind Alliance guidebook (http://
www.jlaguidebook.org/).
Ethics
This project was approved by the Medical School Research
Ethics Committee, University of Nottingham, U.K, Ethics
Reference No. G⁄2⁄2009.
Statistical methods
We aimed for a minimum of 100 participants in the consult-
ation and the ranking exercise and for 20 participants for the
ﬁnal prioritization workshop. This sample size was estimated
on the basis of previous JLA PSPs,
18 and determined by the
time frame available for the vitiligo PSP.
Data from all stages were stored and analysed in Access
2007 and processed by the Steering Group members.
Results
Stages 2 and 3: Consultation and collation
Of the 2303 surveys circulated, 461 (20%) were returned.
This resulted in 1427 questions about vitiligo. Non-treatment
questions (n = 767), about the natural history of vitiligo, its
aetiology and prevention, were excluded.
The response rate for members of the Vitiligo Society was
24% (307⁄1268) and for BAD⁄UK DCTN members was 14%
(119⁄835). Sixty-six per cent of responses (302⁄461) were
from patients, 31% (142⁄461) were from healthcare profes-
sionals, and 3% were from other sources. More women
responded than men (53% women, 30% men, 17% did not
specify), and most were aged 30–60 years (8% < 30 years,
50% 30–60 years, 25% > 60 years, 17% did not specify).
Overall, 660 uncertainties that speciﬁcally related to the
treatment of vitiligo were gathered during the consultation
stage. Thirty-one per cent were from healthcare professionals
(206⁄660), 48Æ5% were from patients (320⁄660) and 20Æ5%
were unknown (134⁄660). An additional 58 treatment
uncertainties were identiﬁed from the BAD guideline and the
updated Cochrane systematic review. The resulting 718 uncer-
tainties were reﬁned into a ‘long-list’ of 93 treatment uncer-
tainties, which were used for the ranking exercise.
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exercise)
In total, 230 people (patients 72%, health care professionals
23%, did not specify 5%) responded to the ranking exercise,
submitting 638 individual votes. Each participant could vote
for up to three of their favourite uncertainties. Nineteen paper
voters were excluded as they submitted more than three
favourite topics. The number of votes per uncertainty ranged
from 49 to 0 (median 5).
The demographic characteristics of participants in the rank-
ing exercise were broadly similar to those in the consultation
stage (63% were women, and 55% were aged between 30
and 60 years). Of those who speciﬁed their ethnicity
(n = 127), 42% were white and 12Æ6% were from black and
ethnic minorities.
As more patients participated in the ranking exercise than
healthcare professionals, the Steering Group considered the
ranked priorities of patients and healthcare professionals separ-
ately.
At the end of this stage, a short-list of 23 uncertainties was
identiﬁed for the ﬁnal prioritization workshop.
Stage 5: Final Prioritization Workshop
The workshop was attended by 47 people: 21 were patients
or patients’ representatives, and 16 were healthcare profes-
sionals (see Acknowledgments section for more details on the
attendees).
Feedback following the workshop showed that all attendees
were either very satisﬁed or satisﬁed with the top 10 uncer-
tainties identiﬁed on the day and the vitiligo PSP was
announced the most successful PSP so far by the JLA.
The top 10 treatment uncertainties for vitiligo as deﬁned by
clinicians and patients were:
1 How effective are systemic immunosuppressants in treating
vitiligo?
2 How much do psychological interventions help people with
vitiligo?
3 Which treatment is more effective for vitiligo: light therapy
or calcineurin inhibitors?
4 How effective is ultraviolet B therapy when combined with
creams or ointments in treating vitiligo?
5 What role might gene therapy play in the treatment of viti-
ligo?
6 How effective are hormones or hormone-related sub-
stances that stimulate pigment cells (melanocyte-stimu-
lating hormone analogues, afamelanotide) in treating
vitiligo?
7 Which treatment is more effective for vitiligo: calcineurin
inhibitors or steroid creams⁄ointments?
8 Which treatment is more effective for vitiligo: steroid
creams⁄ointments or light therapy?
9 How effective is the addition of psychological interventions
to patients using cosmetic camouﬂage for improving their
quality of life?
10 How effective is pseudocatalase cream (combined with
brief exposure to ultraviolet B) in treating vitiligo?
In addition, two treatment uncertainties were suggested as
‘ones to watch’, as these interventions were still in an early
investigative stage.
11 How effective is piperine (black pepper) cream in treating
vitiligo?
12 What role might stem cell therapy play in treating vitiligo?
Finally, important recurring themes for researchers to
consider when developing future trials emerged and are
summarized below (Table 1). These themes covered general
issues that were relevant to all therapeutic interventions for
vitiligo.
Figure 2 presents a summary of the results of the vitiligo
PSP.
Discussion
Vitiligo has traditionally been given a relatively low priority in
the dermatology research agenda, as shown by the number
and quality of studies on vitiligo to date.
9 The updated sys-
tematic review
9 is helpful in identifying many important
research gaps for clinical trials, but these have come largely
from the research community, and may not reﬂect the ques-
tions that patients and clinicians have.
Implication for research
The identiﬁed uncertainties provide a steer for future research
activity by guiding researchers and funding bodies to ques-
tions of importance to patients and healthcare professionals.
All of the uncertainties have been added to DUETs, and are
freely available at http://www.library.nhs.uk/DUETs/Default.
aspx. At this point it is important to remember that the viti-
ligo PSP aims to identify ‘treatment uncertainties’. These are
then used as reference to inform future ‘research questions’ as
developed by individual research teams. It is entirely possible
that one treatment uncertainty will result in several related
research questions.
Table 1 General themes to be considered when designing future
vitiligo trials
General theme
1 Which treatments are effective and safe for children?
2 Do treatment success rates differ according to the site(s)
affected, or the gender ⁄age ⁄ethnicity ⁄skin phototypes of
patients?
3 What are the long-term outcomes of treatments for vitiligo
(especially side-effects)?
4 What is the optimal duration and optimal timing for
treatments of vitiligo?
5 What is the optimal maintenance regimen in order to
prevent relapse?
6 Interventions for segmental vitiligo
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vitiligo identiﬁed, we recommend:
1 More research on the effectiveness and safety of systemic
immunosuppresants for the treatment of vitiligo such as
methotrexate or ciclosporin. Research in this ﬁeld would
potentially contribute to our knowledge about the aetiology of
the disease, which is believed to have a strong autoimmune
component
19,20 (uncertainty 1).
2 Evaluation of currently available and widely used treatments
such as topical corticosteroids and calcineurin inhibitors in a
‘head-to-head’ randomized controlled trial (uncertainty 7).
3 Evaluation of the effectiveness and safety of narrowband
ultraviolet B. More detailed information is needed to answer
questions such as ‘should the ﬁrst line treatment for vitiligo
be topical agents (topical steroids or calcineurin inhibitors) or
more aggressive intervention such as narrowband ultraviolet
B?’ A factorial trial design could evaluate all three treatment
options in one trial (uncertainties 3 and 8).
4 Evaluation of psychological interventions by conducting a
systematic review of the current literature, and substantial
pilot⁄exploratory qualitative work prior to progressing to a full
randomized controlled trial. Together with active treatments,
psychological interventions are believed to be of great impor-
tance. More evidence is needed to establish the role of psycho-
logical support as monotherapy (uncertainty 2), as well as in
combination with other treatments for vitiligo (uncertainty 9).
5 Evaluation of innovative treatments such as afamelanotide
and pseudocatalase, which seem to be important and promis-
ing both to clinicians and to patients (uncertainties 6 and 10).
6 Evaluation of narrowband ultraviolet B combination thera-
pies with topical agents, which also reﬂects the current
research trend, shown by the Cochrane systematic review that
combination treatments seem to be more effective than mono-
therapies
9 (uncertainty 4).
7 More research to be done into the pathophysiology and the
aetiology of the disease based on the great interest expressed
by clinicians and patients on exploration of potential effective-
ness of gene therapy and stem cells (uncertainty 5 and ‘one to
watch’ uncertainty 12).
To conclude, we wish to note that by recommending
the above we are not commenting on the legitimacy of the
interventions that have been prioritized, but are reporting
what clinicians and patients identiﬁed as important research
topics in order to meet their needs.
Reﬂections on the process
One might argue that the response rate for the vitiligo PSP
was rather low (consultation stage response rate 20%); how-
ever, the number of participants by far exceeded our expect-
ations based on previous PSPs convened by the JLA. This was
due mainly to our collaboration and networking with the UK
DCTN and the Vitiligo Society. We believe that the innovative
and unusual nature of this project means that it is inappropri-
ate to apply the same criteria for the response rate of this PSP
as for other surveys. Indeed, the vitiligo PSP far exceeded our
original sample size estimates for the number of participants
at each stage, and had approximately double the number of
participants who took part in previous PSPs.
18
In order to inform future PSPs, it is helpful to present some
of the key challenges that we faced as two recommendations.
Recommendation 1. We recommend that information about the
existing research evidence for the different treatments is pre-
sented in a patient-friendly format at the beginning of the
PSP. This would allow all participants to engage in the process
more effectively, regardless of their background, experience or
levels of expertise.
Recommendation 2. Most of the uncertainties (during consult-
ation) were broad and nonspeciﬁc, or did not specify the
Consultation
2303 surveys sent 
461 people replied  
1427 uncertainties: 
660 treatment uncertainties (46%) 
718 treatment uncertainties  
Ranking exercise
230 people voted  
Short list: top 23 treatment uncertainties  
Collation












Top 10 treatment uncertainties
Fig 2. Summary of the results of the vitiligo priority setting
partnership. BAD, British Association of Dermatologists.
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when others from the research community were very focused.
For that reason, we recommend keeping the uncertainties as
broad as possible to allow ﬂexibility but sufﬁciently narrow to
ensure the question is meaningful. Therefore we have devel-
oped a standard format for different types of questions sub-
mitted (Table 2).
Implementation of the results
The next step of our research group is to conduct a feasibility
study on one of the top 10 uncertainties by working with the
UK DCTN (http://www.ukdctn.org/home/).
We are hopeful that by publishing this list of important
treatment uncertainties, we will prompt other research groups
and pharmaceutical companies to take a fresh look at vitiligo
research and the needs of patients with vitiligo and to bring
unity to the international efforts into the treatment of vitiligo.
Finally, we would recommend that researchers continue to
work with patients and clinicians in meaningful partnerships
in developing their future research activity, in line with
current guidelines.
21
What’s already known about this topic?
• Sixty-eight treatments for vitiligo have been evaluated in
clinical trials over the last 43 years. However, due to the
small numbers of participants and heterogeneity of
design of trials to date, it is difﬁcult to make ﬁrm rec-
ommendations for clinical practice.
• It is increasingly recognized that patients and healthcare
professionals have a key role to play in identifying
important areas for research. The pharmaceutical and
medical technology industries and academia play an
essential role in developing new treatments. However,
the priorities of industry and academics are not necessa-
rily the same as those of patients and clinicians. For this
reason, many areas of potentially valuable research are
neglected.
What does this study add?
• The research areas identiﬁed provide a steer for future
research activity by guiding researchers and funding
bodies to questions of importance to patients and
healthcare professionals. There is a great need for better
evaluation of the currently available and widely used
treatments, such as topical corticosteroids, calcineurin
inhibitors and phototherapy in a ‘head-to-head’ ran-
domized controlled trial.
• Together with active treatments, psychological interven-
tions are of great importance to patients and clinicians.
More evidence is needed to establish the role of psycho-
logical support as monotherapy, as well as in combin-
ation with other treatments for vitiligo.
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effective in treating


















yet on the market (e.g.
gene therapy, stem cell
therapy)
What role might
[treatment X] play in
the treatment of vitiligo?
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